GL CHEMTEC Opens GMP Kilo Facility to Support First-in-Human Trials

• GL CHEMTEC has completed its new GMP Kilo lab facility to support clinical trial material production.

• The expansion strengthens its position as a CDMO offering end-to-end services from pre-clinical to commercial scale.

GL CHEMTEC, a North American-based CDMO, has announced the completion and operational launch of its new Good Manufacturing Practice (GMP) Kilo lab facility. The site is designed to meet growing customer demand for clinical-grade materials, particularly those required for first-in-human trials.

The newly built facility enhances GL CHEMTEC’s capabilities in contract manufacturing by bridging the gap between pre-clinical development and clinical trial supply. According to the company, the investment supports more efficient scaling, faster timelines, and improved quality control.

Located within its existing infrastructure, the GMP Kilo lab includes two ISO 8-qualified rooms, upgraded quality control systems, and the ability to produce materials at multi-kilogram scale. The facility also features a dedicated team of experts in biomedical polymer science and drug delivery.

“This new Kilo lab GMP facility represents a significant milestone in GL CHEMTEC’s growth strategy,” said Dr. Gamil Alhakimi, CEO. “We are now better positioned to support our partners in navigating the complexities of scale-up and clinical trials, ultimately contributing to a healthier future.”

The lab is now accepting new projects and is intended to serve both existing and prospective pharmaceutical and biotech clients.